EXAS’ 3Q14 PR had a curiously understated opening: http://finance.yahoo.com/news/exact-sciences-reports-third-quarter-113000638.html Exact reported total revenues of $0.0 million for the third quarter of 2014, compared to $1.0 million for the third quarter of 2013. Of course, Cologuard wasn’t launched in time to book any sales during 3Q14. EXAS had $211M in cash as of 9/30/14, and it should soon be cash-flow positive.